Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)

[1]  M. Konopleva,et al.  Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax , 2021, Cancer.

[2]  M. Andreeff,et al.  Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML. , 2021, Blood.

[3]  M. Konopleva,et al.  Outcomes in patients with newly diagnosed TP53‐mutated acute myeloid leukemia with or without venetoclax‐based therapy , 2021, Cancer.

[4]  M. Andreeff,et al.  Therapeutic implications of menin inhibition in acute leukemias , 2021, Leukemia.

[5]  Michael R. Green,et al.  Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells , 2021, Blood Cancer Journal.

[6]  W. El-Deiry,et al.  Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[7]  Yongcheng Song,et al.  Structure, function and inhibition of critical protein–protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins , 2021, Journal of Hematology & Oncology.

[8]  T. Cierpicki,et al.  Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations. , 2020, Blood.

[9]  M. Konopleva,et al.  Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. , 2020, Blood advances.

[10]  B. Falini,et al.  NPM1-mutated acute myeloid leukemia: from bench to bedside. , 2020, Blood.

[11]  S. Armstrong,et al.  Synergistic Targeting of FLT3 Mutations in AML via Combined Menin-MLL and FLT3 Inhibition. , 2020, Blood.

[12]  B. Yan,et al.  AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy. , 2020, Experimental hematology.

[13]  M. Levis,et al.  Gilteritinib: potent targeting of FLT3 mutations in AML. , 2020, Blood advances.

[14]  S. Armstrong,et al.  Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia , 2020, Science.

[15]  K. Ross,et al.  A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. , 2019, Cancer cell.

[16]  C. Schmitt,et al.  Cellular Senescence: Defining a Path Forward , 2019, Cell.

[17]  Donna Neuberg,et al.  A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies , 2019, Science.

[18]  Jing Wang,et al.  Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models , 2019, Haematologica.

[19]  K. Rajapakshe,et al.  Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells , 2019, Blood Cancer Journal.

[20]  P. Qiu,et al.  Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML , 2018, Leukemia.

[21]  S. Armstrong,et al.  HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis. , 2018, Cancer cell.

[22]  E. Kjeldsen,et al.  Systematic evaluation of signal-to-noise ratio in variant detection from single cell genome multiple displacement amplification and exome sequencing , 2018, BMC Genomics.

[23]  Charles Y. Lin,et al.  Mutant NPM1 Maintains the Leukemic State through HOX Expression. , 2018, Cancer cell.

[24]  T. Pabst,et al.  The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia , 2018, Cancers.

[25]  T. Cierpicki,et al.  Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction. , 2018, Journal of medicinal chemistry.

[26]  Scott W. Lowe,et al.  Putting p53 in Context , 2017, Cell.

[27]  V. Rotter,et al.  Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy. , 2017, Blood.

[28]  Jian Du,et al.  Preclinical characterization of abemaciclib in hormone receptor positive breast cancer , 2017, Oncotarget.

[29]  A. Ashkenazi,et al.  From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors , 2017, Nature Reviews Drug Discovery.

[30]  F. Nigsch,et al.  Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia , 2017, Leukemia.

[31]  Bo Wen,et al.  Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. , 2015, Cancer cell.

[32]  X. Hua,et al.  Menin: a scaffold protein that controls gene expression and cell signaling. , 2013, Trends in biochemical sciences.

[33]  C. Allis,et al.  Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. , 2010, Molecular cell.

[34]  Jiaying Tan,et al.  The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. , 2010, Cancer cell.

[35]  M. Cleary,et al.  A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. , 2010, Cancer cell.

[36]  Akihiko Yokoyama,et al.  Menin critically links MLL proteins with LEDGF on cancer-associated target genes. , 2008, Cancer cell.

[37]  R. Humphries,et al.  Unraveling the crucial roles of Meis1 in leukemogenesis and normal hematopoiesis. , 2007, Genes & development.

[38]  Scott A. Armstrong,et al.  MLL translocations, histone modifications and leukaemia stem-cell development , 2007, Nature Reviews Cancer.

[39]  D. Kioussis,et al.  Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. , 2007, Cell stem cell.

[40]  Matthew Meyerson,et al.  The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis , 2005, Cell.

[41]  R. Humphries,et al.  Hox regulation of normal and leukemic hematopoietic stem cells , 2005, Current opinion in hematology.

[42]  O. Rozenblatt-Rosen,et al.  Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. D. Hanson,et al.  MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Meyerson,et al.  Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia. , 2019, Experimental hematology.